These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9562600)

  • 1. Novel biological response modifiers derived from thalidomide.
    Hashimoto Y
    Curr Med Chem; 1998 Jun; 5(3):163-78. PubMed ID: 9562600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural development of biological response modifiers based on thalidomide.
    Hashimoto Y
    Bioorg Med Chem; 2002 Mar; 10(3):461-79. PubMed ID: 11814832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel biological response modifiers: phthalimides with TNF-alpha production regulating activity].
    Miyachi H; Azuma A; Hashimoto Y
    Yakugaku Zasshi; 1997 Feb; 117(2):91-107. PubMed ID: 9084226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide analogs from diamines: Synthesis and evaluation as inhibitors of TNF-alpha production.
    de Almeida MV; Teixeira FM; de Souza MV; Amarante GW; Alves CC; Cardoso SH; Mattos AM; Ferreira AP; Teixeira HC
    Chem Pharm Bull (Tokyo); 2007 Feb; 55(2):223-6. PubMed ID: 17268092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence.
    Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y
    Biochem Biophys Res Commun; 1996 Sep; 226(2):439-44. PubMed ID: 8806653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production.
    Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y
    Biochem Biophys Res Commun; 1996 Jul; 224(2):426-30. PubMed ID: 8702405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide: current and potential clinical applications.
    Calabrese L; Fleischer AB
    Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulators of tumor necrosis factor alpha production bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore.
    Tsuji M; Koiso Y; Takahashi H; Hashimoto Y; Endo Y
    Biol Pharm Bull; 2000 Apr; 23(4):513-6. PubMed ID: 10784439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide.
    Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y
    Biol Pharm Bull; 1999 Feb; 22(2):224-6. PubMed ID: 10077449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.
    Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG
    J Immunol; 1998 Oct; 161(8):4236-43. PubMed ID: 9780198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.
    Tramontana JM; Utaipat U; Molloy A; Akarasewi P; Burroughs M; Makonkawkeyoon S; Johnson B; Klausner JD; Rom W; Kaplan G
    Mol Med; 1995 May; 1(4):384-97. PubMed ID: 8521296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural development of synthetic retinoids and thalidomide-related molecules.
    Hashimoto Y
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S16-23. PubMed ID: 12819930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical basis for the activity of thalidomide.
    Meierhofer C; Dunzendorfer S; Wiedermann CJ
    BioDrugs; 2001; 15(10):681-703. PubMed ID: 11604049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues.
    Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K
    Chirality; 1996; 8(5):390-6. PubMed ID: 8900028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
    Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzylphthalimides and phenethylphthalimides with thalidomide-like activity on the production of tumor necrosis factor alpha.
    Sasaki K; Shibata Y; Hashimoto Y; Iwasaki S
    Biol Pharm Bull; 1995 Sep; 18(9):1228-33. PubMed ID: 8845811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide: 40 years on.
    Diggle GE
    Int J Clin Pract; 2001 Nov; 55(9):627-31. PubMed ID: 11770361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory assays to study structure-activity relationships of thalidomide.
    Shannon EJ; Morales MJ; Sandoval F
    Immunopharmacology; 1997 Jan; 35(3):203-12. PubMed ID: 9043933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New indications for thalidomide?].
    Tuinmann G; Hegewisch-Becker S; Hossfeld DK
    Dtsch Med Wochenschr; 2001 Oct; 126(42):1178-82. PubMed ID: 11607859
    [No Abstract]   [Full Text] [Related]  

  • 20. Thalidomide: a review of approved and investigational uses.
    Matthews SJ; McCoy C
    Clin Ther; 2003 Feb; 25(2):342-95. PubMed ID: 12749503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.